144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)

144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)

144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)

144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)

144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)

10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)

8-K - Nautilus Biotechnology, Inc. (0001808805) (Filer)

144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)

144 - Nautilus Biotechnology, Inc. (0001808805) (Subject)

10-Q - Nautilus Biotechnology, Inc. (0001808805) (Filer)

SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

SC 13D/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

SC 13G - Nautilus Biotechnology, Inc. (0001808805) (Subject)

SC 13G/A - Nautilus Biotechnology, Inc. (0001808805) (Subject)

SC 13G - Nautilus Biotechnology, Inc. (0001808805) (Subject)

SC 13D - Nautilus Biotechnology, Inc. (0001808805) (Subject)

SEATTLE, Sept. 17, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for comprehensively quantifying the proteome, today announced the appointment of Kentaro (Ken) Suzuki as Chief Marketing Officer. Mr. Suzuki joins Nautilus after 25 years in product and marketing leadership roles at Agilent Technologies, most recently serving as Vice President and General Manager of Agilent's Mass Spectrometry division. He has held numerous leadership positions at Agilent, including in the Strategic Program Office and Certified Pre-Owned Instruments, CrossLab Services and Support, and Spectroscopy. "Ke

SEATTLE, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the expansion of its research and development senior leadership team with the appointment of Martin Huber, Ph.D., as Vice President of Biochemistry and Flow Cell Development. Dr. Huber brings to Nautilus over 20 years of experience in biotechnology start-ups both in Europe and the US, most recently as founder, CTO and, ultimately, CEO of Quantapore, a company devoted to pioneering massively parallel, direct, single-molecule DNA and protein analytical tools. Prior to that, he he

SEATTLE, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced further expansion of its management team with the appointments of Eric Spence as Vice President of Instrument Engineering and Ken Kuhn, Ph.D., as Vice President of Reagent and Platform Development. Both executives join the company's product development team. Eric Spence, Vice President of Instrument Engineering: Instrument engineering veteran Eric Spence comes to Nautilus from Genapsys, where he advanced through several positions of increasing responsibility leading the instrum

SEATTLE, April 12, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointments of Gwen Weld as Chief People Officer and Sheri Wilcox, Ph.D., as Vice President of Affinity Reagent Development, adding further experience to its senior leadership team in its ongoing expansion of the organization. Gwen Weld, Chief People Officer Gwen Weld brings to Nautilus more than 25 years of senior leadership in human resources, organizational culture, and business strategy. Immediately prior to joining the company, Ms. Weld served as Interim Chief Peopl

SEATTLE, March 31, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karen Akinsanya, Ph.D., to its Board of Directors. Dr. Akinsanya brings more than 25 years of experience in drug discovery and development, commercialization, partnerships, and licensing from across academia and pharmaceutical research and development (R&D). In her current role as President of R&D, Therapeutics at Schrödinger, she leads the company's therapeutics group that leverages Schrödinger's leading physics-based platform for preclinical drug discovery

SEATTLE, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the appointment of Karl Voss, Ph.D., as Vice President of Life Sciences Research and Development. He and his team will work out of Nautilus' research headquarters in San Carlos, California. Dr. Voss brings more than 20 years of experience directing single-molecule biophysics and biochemistry, cell biology, and materials science research at leading biotechnology and life sciences companies. He was previously Vice President of Consumables Research and Development at Pacific Biosc

Guggenheim initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $6.00

Jefferies resumed coverage of Nautilus Biotechnology with a rating of Hold and set a new price target of $3.00

Morgan Stanley initiated coverage of Nautilus Biotechnology with a rating of Equal-Weight and set a new price target of $8.00

Cowen & Co. initiated coverage of Nautilus Biotechnology with a rating of Outperform

Goldman Sachs initiated coverage of Nautilus Biotechnology with a rating of Neutral and set a new price target of $10.00

Jefferies initiated coverage of Nautilus Biotechnology with a rating of Buy and set a new price target of $13.00

SEATTLE, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus")), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2024. "I'm excited about the expanding opportunity I see for proteomics and am pleased with the progress we're making as a business," said Sujal Patel, CEO of Nautilus. "We consistently receive positive feedback from researchers around the world as they tell us of their desire to explore the proteome more deeply and more broadly, and of the significant limitations of what's currently available. It is becoming ever more apparent that they understand

SEATTLE, Oct. 08, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the third quarter 2024 before market open on Tuesday, October 29, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and i

SEATTLE, July 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule proteome analysis platform, today reported financial results for the second quarter ended June 30, 2024. "In Q2, we saw continued progress against core development goals for each of the components of our platform," said Sujal Patel, CEO of Nautilus. "We believe we are pioneering a fundamentally new approach that holds the potential to overcome the limitations of traditional and peptide-based protein analysis methods and to unlock the value of the proteome – both in targeted proteoform analysis and broadscale discovery – something we continue to vie

SEATTLE, July 09, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the second quarter 2024 before market open on Tuesday, July 30, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its

SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the first quarter ended March 31, 2024. "We continued to make solid progress against our core development goals in Q1," said Sujal Patel, CEO of Nautilus.   "We remain incredibly focused on increasing the scale, stability, and reproducibility of our consumables, assay, instrument, and software and continue to see meaningful gains along each of those dimensions. We are clear-eyed about what work remains to be done and confident that we have a foundational understanding of what is requ

SEATTLE, April 11, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the first quarter 2024 before market open on Tuesday, April 30, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and it

SEATTLE, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2023. "2023 was a year of significant accomplishment and foundational progress for Nautilus; progress that will continue to build our momentum as we move through 2024 and into the planned launch of our proteome analysis platform", said Sujal Patel, CEO of Nautilus. "We are building a groundbreaking, ‘first-in-the-world' platform designed to unlock significant breakthroughs in biological research. Doing so requires that a number of

SEATTLE, Feb. 07, 2024 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2023 before market open on Wednesday, February 28, 2024. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seat

SEATTLE, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2023. "I'm very pleased with the progress Nautilus made in Q3 as we continue our drive towards commercial readiness", said Sujal Patel, CEO of Nautilus.   "Continuing to increase the scale and robustness of the platform remains a key area of focus as we ready the platform for launch next year. With an increasing focus on proteomics by the scientific community, moves by major life science companies to expand their proteomics-related offerings,

SEATTLE, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ:NAUT, or "Nautilus"))), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the third quarter before market open on Tuesday, October 31, 2023. The company's management will webcast a corresponding conference call beginning at 5:30 a.m. Pacific Time / 8:30 a.m. Eastern Time to discuss its results, business developments, and outlook. Live audio of the webcast will be available on the "Investors" section of the company website at: www.nautilus.bio. About Nautilus Biotechnology, Inc.With its corporate headquarters in Seattle, Washington and its re

Guggenheim analyst Subbu Nambi initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Buy rating and announces Price Target of $6.

Jefferies analyst Tycho Peterson assumes Nautilus Biotechnology (NASDAQ:NAUT) with a Hold rating and lowers Price Target of $3.

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.17) by 11.76 percent. This is a 25 percent decrease over losses of $(0.12) per share from the same period last year.

Gainers Avalo Therapeutics (NASDAQ:AVTX) stock rose 289.1% to $18.48 during Friday's pre-market session. The market value of their outstanding shares is at $14.8 million. Xilio Therapeutics (NASDAQ:XLO) stock moved upwards by 205.16% to $1.95. The market value of their outstanding shares is at $53.6 million. Biodexa Pharmaceuticals (NASDAQ:BDRX) shares moved upwards by 78.11% to $1.53. The market value of their outstanding shares is at $6.5 million. Akanda (NASDAQ:AKAN) shares moved upwards by 50.45% to $0.25. The company's market cap stands at $2.1 million. iBio (AMEX:IBIO) shares moved upwards by 27.98% to $4.3. The market value of their outstanding shares is at $14.9 million. Mesobl

Nautilus Biotechnology (NASDAQ:NAUT) reported quarterly losses of $(0.14) per share which beat the analyst consensus estimate of $(0.15) by 6.67 percent. This is a 27.27 percent decrease over losses of $(0.11) per share from the same period last year.

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenue of $1.69 billion. • Golden Ocean Group (NASDAQ:GOGL) is likely to report quarterly earnings at $0.27 per share on revenue of $193.12 million. • Wallbox (NYSE:WBX) is likely to report earnings for its fourth quarter. • Immunocore Hldgs (NASDAQ:IMCR) is estimated to report quarterly loss at $0.28 per share on revenue of $67.23 million. • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.08 per share on revenue of $9.95 billion. • TG Therapeutics (NASDAQ:TGTX) is likely to report quarterly loss at $0.10 per share on revenue of $40.06 mil